Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain



Status:Active, not recruiting
Conditions:Arthritis, Osteoarthritis (OA)
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:35 - 75
Updated:4/21/2016
Start Date:October 2014
End Date:June 2016

Use our guide to learn which trials are right for you!

A Muti-Center, Prospective, Double-Blind, Randomized Controlled Study to Evaluate the Effectiveness and Safety of the Iovera° Device for the Temporary Relief of Pain Associated With Knee Osteoarthritis

This purpose of this study is to evaluate the effectiveness and safety of the iovera° device
for the temporary reduction of pain associated with knee osteoarthritis.


Inclusion Criteria:

Inclusion Criteria

- 35 - 75 years of age

- American College of Rheumatology (ACR) criteria for osteoarthritis of the knee. This
includes radiographic evidence of osteophytes and at least one of the following: age
≥ 50 years old, morning stiffness ≤ 30 minute duration or crepitus on motion.

- Grade II or III osteoarthritis of the knee as determined by Kellgren-Lawrence
classification grading scale on anteroposterior (AP) x-ray within previous 6 months.

- Subjects are ambulatory without assistive devices.

- Knee pain of ≥ 40 mm on Visual Analog Scale (VAS) when performing one of two
movements that elicit the worst pain: standing from a seated position or walking
up/down stairs.

- Subject reports knee pain in the anterior and/or inferior aspect of the knee as
documented on the knee pain map in the appropriate areas.

- A diagnostic lidocaine (without epinephrine) block of the infrapatellar branch of the
saphenous nerve results in a 50% reduction in the VAS pain assessment score when
performing the activity that elicits the worst pain: standing from a seated position
or walking up/down stairs.

- Subject is able to tolerate a washout of prescription and over-the-counter pain
relief for a duration of 5X the half life of the medication prior to the Baseline
visit.

Subject is able to tolerate a washout of adjunctive therapies for knee pain for 72 hours
prior to the Baseline visit.

- Western Ontario and McMaster Osteoarthritis Index (WOMAC) NRS3.1 Pain subscore ≥ 20
at Baseline/Visit 2.

- Subject is able to tolerate discontinuation of all pain medication throughout the
duration of the study. Acetaminophen may be used as rescue medication with a maximum
dose of 4g per day.

- Subject is able to tolerate discontinuation of rescue medication, acetaminophen, for
24 hours prior to all follow-up visits.

- Prescription and over-the-counter pain medications must be maintained on a stable
schedule for at least two weeks prior to screening.

- Subject is willing and able to give written informed consent.

- Subject is willing and able to comply with study instructions and commit to all
follow-up visits for the duration of the study.

- Subject is in good general health and free of any systemic disease state or physical
condition that might impair evaluation or which in the Investigator's opinion,
exposes the Subject to an unacceptable risk by study participation.

Exclusion Criteria:

- History of a partial or full knee replacement of the knee to be treated.

- Planned partial or full knee replacement within the next 12 months in knee to be
treated.

- Previous myoscience FCTTM treatment.

- Viscosupplementation within the previous 6 months in knee to be treated.

- Subject reports the majority of knee pain outside of the anterior/inferior aspect of
the knee.

- Intra-articular steroid injection in the knee to be treated within previous 3 months.

- Gross deformity of the knee including varus or valgus.

- Started physical therapy of the knee to be treated within 3 months of screening.

- Received acupuncture for knee pain within 3 months prior to screening.

- Body Mass Index ≥ 35.

- Prior surgery in the treatment area that may alter the anatomy of the infrapatellar
branch of the saphenous nerve or result in scar tissue in the treatment area.

- Open and/or infected wound in the treatment area.

- Disease of the spine, hip, contralateral knee or other lower extremity joint of
sufficient degree affecting the assessment of the treated knee.

- Acetaminophen intolerance or allergy.

- Allergy to lidocaine.

- History of cryoglobulinemia

- History of paroxysmal cold hemoglobinuria.

- History of cold urticaria.

- History of Raynaud's disease.

- History of pes anserinus bursitis in the knee to be treated.

- Use of extended-release or long-acting opioids within previous 3 months.

- Use of immediate-release opioids for more than 3 days per week within previous month.

- Subject is pregnant or planning to become pregnant while enrolled in the study.

- Current enrollment in any investigational drug or device study or participation
within 30 days prior to screening.

- Any additional diagnosis that in the opinion of the Investigator directly contributes
to knee pain.

- Any concomitant inflammatory disease or other condition that affects the joints (e.g.
rheumatoid arthritis, metabolic bone disease, gout, active infection, etc.)

- Any clotting disorder and/or use of an anticoagulant (e.g., aspirin, warfarin,
clopidogrel, etc.) within seven (7) days prior to administration of the device.

- Any local skin condition at the treatment site that in the Investigator's opinion
would adversely affect treatment or outcomes.

- Any chronic medical condition that in the Investigator's opinion would prevent
adequate participation.

- Any chronic medication use (prescription, over-the-counter, etc.) that in the
Investigator's opinion would affect study participation or Subject safety.

- For any reason, in the opinion of the Investigator, the Subject may not be a suitable
candidate for study participation (i.e., history of noncompliance, drug dependency,
any related knee injury due to a worker's compensation claim, etc.).

- Known liver dysfunction.
We found this trial at
17
sites
Boise, Idaho 83713
Principal Investigator: Richard Radnovich, D.O.
Phone: 208-939-2100
?
mi
from
Boise, ID
Click here to add this to my saved trials
Altoona, Pennsylvania 16602
Principal Investigator: Shawn Saylor, D.O.
Phone: 814-944-4532
?
mi
from
Altoona, PA
Click here to add this to my saved trials
Bradenton, Florida 34203
Principal Investigator: Alan Valadie, M.D.
Phone: 941-782-1353
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Covina, California 91723
Principal Investigator: Samy Kamal Metyas, M.D.
Phone: 626-869-5730
?
mi
from
Covina, CA
Click here to add this to my saved trials
Covington, Louisiana 70433
Principal Investigator: Kevin F. Darr, M.D.
Phone: 985-892-5117
?
mi
from
Covington, LA
Click here to add this to my saved trials
Durham, North Carolina 27704
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fairway, Kansas
Principal Investigator: Niel Segal, MD
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Fort Lauderdale, Florida 33316
Principal Investigator: Kevin Shrock, M.D.
Phone: 954-559-6090
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Frederick, Maryland 21702
Principal Investigator: Nathan Wei, M.D.
Phone: 310-624-1168
?
mi
from
Frederick, MD
Click here to add this to my saved trials
Jupiter, Florida 33458
Principal Investigator: Ronald Surowitz, D.O.
Phone: 561-741-2033
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
Knoxville, Tennessee 37909
Principal Investigator: James Choo, M.D.
Phone: 865-934-2570
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Vinod Dasa, MD
Phone: 504-568-4640
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Overland Park, Kansas 66211
Principal Investigator: Atul T Patel, M.D.
Phone: 913-381-5225
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Rockford, Illinois 61107
Principal Investigator: Richard Olson, M.D.
Phone: 815-484-6942
?
mi
from
Rockford, IL
Click here to add this to my saved trials
Sacramento, California 95827
Principal Investigator: Nancy Lane, M.D.
Phone: 916-734-8538
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
South Miami, Florida 33143
Principal Investigator: Julian Naranjo, MD
Phone: 786-220-6738
?
mi
from
South Miami, FL
Click here to add this to my saved trials
Spokane, Washington 99218
?
mi
from
Spokane, WA
Click here to add this to my saved trials